Sangeeta, I wouldn’t think big data could really retrospectively prove causation, only strong associations, and there have been population studies in multiple journals by now. I think there might need to be some pathophysiologic research that shows a causative mechanism as well as a prospective study for me to truly buy it.
I’ve had a run of patients with bilateral simultaneous or sequential NAION who are on Semaglutide, but honestly, it feels like half of veterans I see are on semaglutide in general, and most (except for 2) have vascular risk factors as well. Almost none of them want to stop the medication. I am definitely worried but trying not to over-associate, especially since I see the same resolution of disc edema and/or incomplete recovery whether we stop it or not.
I would be eager to participate in anyone’s trial that is looking into this further.
Kim
Original Message:
Sent: 7/17/2025 8:57:00 AM
From: Sangeeta Khanna
Subject: RE: Bilateral naion semaglutide
Would a NANOS registry of such patients (bilateral/rapid sequential, especially) help or is the answer of causation going to come from big data stats only?
Sangeeta
Sangeeta Khanna MD
University of Michigan
Original Message:
Sent: 7/17/2025 8:17:00 AM
From: Larry Frohman
Subject: RE: Bilateral naion semaglutide
thanks
Sent from my iPhone